Methotrexate and Fludarabine combination

The combination of methotrexate and fludarabine has been studied primarily for **severe refractory rheumatoid arthritis**. **Mechanism of Action**: * Methotrexate is an antimetabolite and antifolate that inhibits dihydrofolate reductase, essential for DNA synthesis and cell division. * Fludarabine is a purine nucleoside analog that inhibits DNA polymerase alpha, ribonucleotide reductase, and DNA primase, resulting in inhibition of DNA synthesis. * *In vitro* studies suggest potential antagonistic cytotoxic effects when administered simultaneously, possibly inappropriate for certain conditions like leukemia. **Clinical Applications**: The primary clinical application studied was in severe refractory rheumatoid arthritis, particularly in patients with inadequate control on methotrexate alone or with other immunosuppressants. **Safety Profile**: Potential safety concerns include: * **Myelosuppression** (neutropenia, thrombocytopenia, anemia), a major dose-limiting effect of fludarabine. * **Neurotoxicity**, including ocular toxicity (though infrequent). * **Immunosuppression** leading to opportunistic infections. * Potential for increased toxicity when combined. Some drug interaction databases advise avoiding or closely monitoring for methotrexate toxicity when used together. **Development Status**: The combination was studied in a clinical trial for severe refractory rheumatoid arthritis but does not appear to have progressed to standard clinical use.